TUSTIN, Calif., May 30 /PRNewswire-FirstCall/ -- AMDL, Inc. , headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (Jade), is an international biopharma company and AMDL, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that Jade, through its subsidiary JJB, has signed a new Distribution and Agency Agreement with Anhui Huayuan Medical Co. Ltd., (AHM) a direct subsidiary of China Resources (Holdings) Co., Ltd. (China Resources).
This one-year renewable agreement covers primarily the provinces and cities of Anhui, Shandong, Hebei, Shanxi, Beijing, Tianjing. AHM will initially be selling 12 Jade products including Ondansetron injectables, Domperidon tablets, Chondroitin Sulfate injectables, GuYanLin compounds, Benzoic Acid /Camphor solutions, Levofloxacin and Lactate injectables and others.
Mr. Frank Zheng, Managing Director of Jade, stated that “this new distribution agreement with AHM coupled with the two new distribution relationships recently announced with Double Crane Medicine Co. Ltd. (Changsha), and Shanghai SiFul Medicine Co., Ltd., all require JJB’s distribution partners to meet minimum sales thresholds of approximately (US) $3.8 million annually for each distribution agreement or a total of approximately (US) $11.4 million for all of these distribution contracts. Based upon all three distribution agreements and discussions between JJB and its new distribution partners, we believe that there is a potential to increase JPI’s sales in Northern China and also the Shanghai regional markets by as much as (US) $24 million over the next 12 month sales cycle. Domperidone tablets are expected to be the largest selling product in these Northern China marketplaces,” Mr. Zheng said.
Mr. Gary Dreher, CEO of AMDL noted that “this new regional Chinese distribution relationship with AHM is truly exciting and significantly enhances Jade’s ability to grow its sales in these Northern China markets.”
About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About Anhui Medical: AHM was found in 1953, and is one of the largest pharmaceutical distributors in China with products ranging from new medicines, generic medicine and health supplements. AHM was recently acquired by China Resource (Holdings) Co., Ltd., which formed one of the largest pharmaceutical businesses in China. China Resource (Holdings), with (U.S.) $8 billion in revenues has four listed subsidiaries on the Hong Kong Stock Exchange, including China Resources Enterprise, Ltd. (Hong Kong Stock Code: 0291), ADR: CRHKY and on the London Stock Exchange and other international exchanges. Currently, AHM has a sales and marketing network that includes more than 4,400 local and provincial based pharmaceutical distributors selling over 25,000 medical products nationwide in China. AHM is ranked as one of the top 3 pharmaceutical distributors in China. In 2006, AHM had sales of approximately US$1.2 billion. In 2003, AHM built the first online pharmacy in China and is currently the largest on-line pharmacy in China.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460
AMDL, Inc.
CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460
Web site: http://www.amdl.com/
